NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.379) was uploaded to the NHS England Website on Wednesday 26, November 2025.
The following changes have been introduced:
Dostarlimab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) (DOS3)
For the 1st line treatment of mismatch repair proficient (pMMR) or microsatellite stable endometrial carcinoma in adult patients who have recurrent or primary advanced disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy but are eligible for systemic therapy where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Obecabtagene autoleucel (OBE01a)
Obecabtagene autoleucel (obecel) CAR-T cells for treating relapsed/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (OBE01b) can only be completed as a continuation of this first part of the form (OBE01a) and OBE01b must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of obecabtagene autoleucel (obecel). Note: the second part of the form (OBE01b) will only appear after the above first part of the form (OBE01a) has been fully completed and submitted. To complete the second part of the form, the user will have to complete a continuation request for the OBE1a application.
Recommended for routine commissioning, receiving CDF interim funding
NA (PEMB32)
NA
Moved into routine commissioning - section B of list